NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Impact · against what's priced in

Natera and CytoDyn's collaboration provides modest positive catalysts for both companies by validating Signatera's utility in clinical trials and providing CytoDyn with molecular data for its mCRC program. The news expands Natera's partnership footprint and strengthens the clinical development path for CytoDyn's leronlimab.

CYDY+0.30

No priced-in read yet